Mo brings PhD-level analytical training and experience across corporate strategy, venture analysis, and biotechnology diligence. He has worked closely with pharmaceutical, biotechnology, and investment teams to evaluate assets, assess risk, and support strategic decision-making across transactions, capital raises, and asset prioritization efforts. Mo combines technical rigor with structured, investment-oriented reasoning to help clients navigate complex scientific and commercial landscapes.